Drug Database
FO

formoterol (Forair / Atimos / CHF 1531)

✓ Approved

Novartis AG · ADRB2 · Small Molecule

What is formoterol?

formoterol is a small molecule developed by Novartis AG. It is approved for therapeutic indications via inhaled or topical.

Drug Profile

Brand NamesForair, Atimos, CHF 1531
CompanyNovartis AG
Drug ClassSmall Molecule
Molecular TargetADRB2
RouteInhaled, Topical
StatusApproved

Mechanism of Action

Molecular Targets

formoterol acts on 1 molecular target:

ADRB2adrenoceptor beta 2 (B2AR, ARB2)
Want deeper analysis?Noah AI can explain complex mechanisms and compare to similar drugs.

Therapeutic Indications

formoterol is developed for 2 unique indications across 1 therapeutic area.

Therapeutic AreaConditionPhase
Respiratory, thoracic and mediastinal disordersAsthma✓ Approved
Respiratory, thoracic and mediastinal disordersChronic obstructive pulmonary disease✓ Approved

Related Research Articles

PubMedAnalytical methods : advancing methods and applications2026-07-17

Exploiting von Pechmann coumarin derivatization for spectrofluorimetric determination of formoterol in pharmaceutical samples with application to content uniformity testing.

Derayea Sayed M SM, Badry Sara I SI, Nagi Dalia M DM, Oraby Mohamed M

A sensitive spectrofluorimetric technique exhibiting acceptable selectivity was established for the quantification of formoterol (FMT) via the von Pechmann condensation reaction, leading to the formation of intensely fluorescent coumarin derivatives. In this reaction, FMT interacts with ethyl acetoacetate in the presence of concentrated sulfuric acid, producing a fluorescent product. The emitted fluorescence was recorded at 445 nm following excitation at 361 nm. Experimental parameters influencing the reaction were carefully optimized to achieve maximum fluorescence response and method stability. The proposed method exhibited excellent linearity across the concentration range of 20-500 ng mL-1, with a correlation coefficient (r) of 0.9998. The limits of detection (LOD) and quantification (LOQ) were found to be 4 ng mL-1 and 12 ng mL-1, respectively. Acceptable selectivity was demonstrated under the studied formulation conditions, as no significant interference was observed from commonly used pharmaceutical excipients, including lactose monohydrate, magnesium stearate, gelatin, titanium dioxide and placebo. A reaction pathway based on the reported von Pechmann condensation was proposed, and the method was validated in accordance with ICH guidelines. The applicability of the method was successfully demonstrated for the determination of FMT in pharmaceutical dosage forms, including content uniformity testing, showing satisfactory recovery results. Finally, the environmental impact of the method was assessed using various greenness evaluation tools, indicating a favorable greenness profile and practical applicability.

PubMedJournal of aerosol medicine and pulmonary drug delivery2026-07-16

Toward Next-Generation Propellants: Assessing Lung Deposition of Beclometasone Dipropionate, Formoterol, and Glycopyrrolate Formulated with HFA-152a Using Functional Respiratory Imaging.

Matturro Angelo A, Monshi Tousi Navid N, Sadafi Hosein H, Cuoghi Erika E et al.

Pressurized metered-dose inhalers (pMDIs) rely on hydrofluoroalkane (HFA) propellants that have a high global warming potential (GWP). Reformulation with next-generation, low-GWP propellants, such as HFA-152a, offers a strategy to reduce climate impact; however, changes in propellant composition can affect aerosol characteristics and potentially alter lung deposition, requiring robust demonstration of therapeutic equivalence. Functional respiratory imaging, combining high-resolution computed tomography and computational fluid dynamics, was used to compare the lung deposition of a fixed triple combination of beclometasone dipropionate, formoterol fumarate, and glycopyrronium bromide (BDP/FF/GB) delivered via a pMDI formulated with either HFA-134a (Reference) or HFA-152a (Test). Ten patients with chronic obstructive pulmonary disease (GOLD stages 2-4) were retrospectively selected. Patient-specific airway geometries, a standardized inhalation profile, and formulation-specific particle size distributions and plume characteristics were applied. Deposition was quantified in the intrathoracic, central + distal, and peripheral lung regions, and the (central + distal)/peripheral ([C + D]/P) deposition ratio was evaluated. Mean intrathoracic deposition was comparable between the Reference and Test formulations, ranging from 45.95% to 46.88% of the delivered dose (DD). Deposition in the central + distal airways accounted for 12% of DD for both formulations, whereas peripheral deposition predominated, with 33.7% of DD for the Test formulation and 34.5% of DD for the Reference formulation. The (C + D)/P ratios were similar across all active components (0.35-0.37), indicating consistent preferential deposition in the peripheral/small airways. Although inter-patient variability was observed, intra-subject comparisons showed close agreement between propellants. Reformulation of the BDP/FF/GB pMDI with the low-GWP propellant HFA-152a preserved total and regional lung deposition characteristics relative to the current HFA-134a formulation. These findings support the maintenance of deposition performance while enabling a substantial reduction in environmental impact, reinforcing the potential of HFA-152a as a next-generation propellant for carbon minimal pMDI therapies.

PubMedJournal of aerosol medicine and pulmonary drug delivery2026-07-16

Mucociliary Clearance Following a Next-Generation Propellant Versus Hydrofluoroalkane-134a via Pressurized Metered-Dose Inhaler: A Randomized, Double-Blind, Two-Way Crossover Study in Healthy Adults.

Donaldson Scott H SH, Zeman Kirby L KL, Bell Alan A, Jassal Mandeep M et al.

Pressurized metered-dose inhalers (pMDIs) are commonly used for respiratory disease treatment but contain propellants, such as hydrofluoroalkane-134a (HFA-134a), with global warming potential (GWP) that contribute to the climate emergency. To safeguard essential medicine access, it is crucial to transition to lower-GWP propellants, such as hydrofluoroolefin-1234ze (HFO-1234ze), which has 99% lower GWP than HFA-134a. In accordance with global regulatory requirements, this study was conducted to support the registration of pMDIs with HFO-1234ze. This randomized, double-blind, multicenter, two-way crossover study assessed the effects of HFO-1234ze versus HFA-134a on mucociliary clearance (MCC) in healthy participants aged 18-60 years. Participants received six inhalations twice daily of HFO-1234ze and HFA-134a in two 7-day (+3) intervention periods separated by a 7- to 14-day washout. The primary and secondary endpoints were change from period-specific baseline in average whole lung MCC (%) through 60 minutes (MCC60) and at 3 hours (MCC3h), respectively, measured via inhalation of 99mTc-labeled colloid and gamma camera imaging. Given significant baseline variability, a post hoc analysis of the primary endpoint assessed change from average baseline instead of period-specific baseline MCC60. Additional safety and tolerability measures were assessed. Forty-five participants were screened; the Primary Analysis Set included 34 participants who completed both intervention periods. For the primary endpoint, change from period-specific baseline in MCC60 was negligible, with an estimated change (95% confidence interval [CI]) of -0.6% (-3.2%, 1.9%) for HFO-1234ze and 0.8% (-1.7%, 3.3%) for HFA-134a. The estimated least-squares mean difference (95% CI) between HFO-1234ze and HFA-134a was -1.4% (-5.8%, 2.9%). For the secondary endpoint, the estimated least-squares mean difference for change from period-specific baseline in MCC3h between HFO-1234ze and HFA-134a was -5.7% (-10.9%, -0.5%). There were no unexpected safety findings. There was no clinically relevant impact of HFO-1234ze versus HFA-134a on MCC in healthy participants. NCT05755932.

PubMedBMC primary care2026-07-16

Barriers and facilitators to practitioner prescribing and patient adoption of anti-inflammatory maintenance and reliever therapy (MART) for adult asthma: a qualitative study.

Dyson Judith J, Cummings Helena H, Williams Gemma G, RajaGopal Vieshal V et al.

Asthma was traditionally treated with separate corticosteroid (ICS) containing ('preventer') and short-acting beta-agonist (SABA; 'reliever') inhalers. But overuse of SABA-reliever inhalers is common and associated with poor outcomes. Clinical guidelines increasingly recommend using combined ICS and formoterol (ICS-formoterol) as an anti-inflammatory reliever. While ICS-formoterol use as a reliever only, without maintenance doses, has only recently been licenced in the United Kingdom; use as both preventer and reliever (Maintenance and Reliever Therapy; MART) has been recommended for many years. Despite the evidenced benefits of this approach, MART uptake in the UK has been low. We studied the barriers and facilitators to primary care practitioners' prescribing and adult asthma patients' adoption of MART. We recruited practitioners and patients from a network of general practices that had participated in the SENTINEL programme to address SABA over-use and support MART adoption. Semi-structured, theoretically underpinned interviews were conducted with both groups. Data analysis involved deductive coding to the theoretical domains framework (a comprehensive framework including all potential determinants of practitioner and health behaviours) followed by inductive coding within domains. Fourteen themes were identified, with novel findings. Facilitators were practitioner knowledge and skills, and practice prescribing and appointment systems. Practitioner barriers mostly related to available resources, changes to treatment following emergency hospital presentations, and managing patient barriers to MART adoption and maintenance. Patient barriers included: psychological dependence on SABA-relievers and associated fear of discontinuation lack of understanding of the rationale for change to MART; and reluctance to change caused by concerns about difficulty getting an appointment if their asthma control deteriorated. Some practitioner barriers reported by previous studies (e.g., guideline knowledge and asthma management skills) were identified as facilitators in our study, potentially due to SENTINEL Programme participation. The Global Initiative for Asthma (GINA) endorse ICS-formoterol as the preferred reliever in asthma, making it vital to understand barriers and facilitators to clinician and patient adoption in practice. We identified unique and previously unreported barriers and facilitators for both groups with potential to inform strategies to support practitioner and patient concordance with anti-inflammatory reliever-based asthma treatment and implementation of evidence-based, guideline-recommended care.

PubMedInternational journal of chronic obstructive pulmonary disease2026-07-15

Comparative Effectiveness and Safety of Fluticasone-Umeclidinium-Vilanterol and Beclomethasone-Glycopyrronium-Formoterol Single-Inhaler Triple Therapies for COPD: Real-World Observational Study [Response to Letter].

Cherian Mathew M, Suissa Samy S

PubMedHealthcare (Basel, Switzerland)2026-07-15

Effectiveness and Safety of Budesonide/Formoterol in Asthma: A Systematic Review.

Vo Nam Xuan NX, Pham Huong Lai HL, Ho Han Tue HT, Chung Khoi Quoc KQ et al.

Background/Objectives: Asthma's preventable burden is heavily driven by severe exacerbations (SE). Replacing standalone short-acting β2-agonists (SABAs), which risk reducing patient tolerance, with inhaled corticosteroid/long-acting β2-agonist combinations optimizes care through maintenance, reliever, and maintenance-and-reliever therapy (MART). This systematic review and meta-analysis evaluated the efficacy, effectiveness, and safety of Budesonide/Formoterol (B/F). Methods: PubMed, Cochrane, and Embase were searched for randomized controlled trials (RCTs) and non-randomized controlled trials (non-RCTs) through May 15, 2026. Bias was assessed via the Cochrane Risk of Bias tool version 2 (RoB 2) and the Risk ff Bias in Non-randomized Studies of Interventions (ROBINS-I) version 2.0. Primary outcomes (time to first SE, annual SE rate) were pooled using a random-effects meta-analysis, yielding hazard ratios (HRs) and rate ratios (RRs). Results: We included 19 studies (15 RCTs, 4 non-RCTs) comprising 104,600 patients (primarily aged ≥12 years with mild-to-severe asthma). Most RCTs had a low risk of bias, whereas the non-RCTs had a high risk of bias. B/F MART significantly delayed the first SE and reduced annual rates versus Budesonide + SABA (HR = 0.57; RR = 0.55), B/F + SABA (HR = 0.62; RR = 0.58), and Fluticasone/Salmeterol + SABA (HR = 0.75; RR = 0.72). As-needed B/F reduced first SE hazard and annual rates versus SABA alone (HR = 0.43; RR = 0.42). Compared with Budesonide + SABA, it delayed the first SE (HR = 0.85) but showed non-significant rate reductions (RR = 0.90). Adverse events were balanced between groups over 12-52 weeks. Conclusions: B/F MART demonstrates high efficacy in mitigating the risk of the first SE. However, limited trial data leave the evidence for maintenance or reliever regimens controversial. Across all regimens, B/F is well-tolerated within 6 to 12 months.

+6091 more articles available with a free account

Sign up free to view all articles →

Ask about formoterol